过去十年来，对急性髓系白血病（AML）进行门诊巩固治疗取得了进展。标准治疗方案包括给予高剂量阿糖胞苷或中度剂量阿糖胞苷，每日两次，连续三天交替使用。在伦敦地区癌症中心，我们已将门诊使用阿糖胞苷的给药方式改为连续六天一次的方案。较长时期内高剂量阿糖胞苷和中度剂量阿糖胞苷的结果目前尚不清楚。本研究旨在评估在门诊环境中连续6天给予高剂量（HDAC-16）和中度剂量阿糖胞苷（IDAC-16）巩固治疗的可行性。这是一项回顾性病例分析，分析伦敦地区癌症中心于2019年1月1日至2022年11月1日期间接受门诊高剂量或中度剂量阿糖胞苷巩固治疗的AML患者。主要目标是确定一次日给药高剂量阿糖胞苷或中度剂量阿糖胞苷连续6天的门诊治疗结果。共有45名患者接受了89个周期的门诊阿糖胞苷治疗；男性占总人口的55.6%，中位年龄约57岁。我们的HDAC-16（57.1%）和IDAC-16（83.3%）的总体2年生存率与已报告的文献一致。HDAC和IDAC组之间在延误、复发率和无复发死亡率方面没有差异。HDAC-16的2年无复发生存率为57.1%，IDAC-16的2年无复发生存率为66.7%。与高剂量阿糖胞苷巩固化疗相比，连续六天每日一次给予中度剂量阿糖胞苷的门诊治疗结果，总体生存率和复发率相似。改为每日一次给药计划，可以减轻门诊肿瘤科的后勤和/或可及性方面的困难。在该背景下，需要进行前瞻性随机试验以验证我们的结果。 ©2023 John Wiley＆Sons A / S. 由John Wiley＆Sons Ltd.发表。

The last decade has seen advances in delivering outpatient consolidation therapy for acute myeloid leukemia (AML). The standard of care involves high-dose cytarabine or intermediate-dose cytarabine, given twice daily for three alternating days. At the London Regional Cancer Program, we have transitioned the administration of outpatient cytarabine to a once-daily regimen over six consecutive days. The outcomes of a longer duration interval of high-dose cytarabine and intermediate-dose cytarabine is currently unknown. This study aims to assess the feasibility of administering a continuous 6-day protocol of high-dose (HDAC-16) and intermediate-dose cytarabine (IDAC-16) consolidation therapy in the outpatient setting.This is a retrospective chart review to analyze AML patients treated with outpatient high-dose or intermediate-dose cytarabine consolidation therapy at the London Regional Cancer Program from January 1, 2019, through November 1, 2022. The primary objective was to determine the outcomes of the 6-day outpatient administration of once daily high-dose cytarabine or intermediate-dose cytarabine.Forty-five patients received 89 cycles of cytarabine as outpatients; males were 55.6% of the total population, with a median age of ~57 years. Our overall 2-year survival of HDAC-16 (57.1%) and IDAC-16 (83.3%) is consistent with the reported literature. There was no difference in delays, relapse rates, and nonrelapse mortality between both HDAC and IDAC groups. The 2-year relapse free survival was 57.1% for HDAC-16 and 66.7% for IDAC-16.Outpatient administration of intermediate-dose cytarabine once daily over six consecutive days results in similar overall survival and relapse rates as compared to high dose cytarabine consolidation chemotherapy. Moving to a once daily administration schedule can alleviate logistical and/or accessibility hurdles for outpatient oncology clinics. Prospective randomized trials are needed in this setting to validate our results.© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.